New developments in the treatment of primary biliary cholangitis – role of obeticholic acid

References

• SelmiCBowlusCLGershwinMECoppelRLPrimary biliary cirrhosisLancet201137797771600160921529926
   PubMed Web of Science ®Google Scholar
• InvernizziPMiozzoMBattezzatiPMFrequency of monosomy X in women with primary biliary cirrhosisLancet2004363940853353514975617
   PubMed Web of Science ®Google Scholar
• SelmiCMayoMJBachNPrimary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environmentGastroenterology2004127248549215300581
   PubMed Web of Science ®Google Scholar
• PanHYDaiYNZhengJNNational incidence of autoimmune liver diseases and its relationship with the human development indexOncotarget2016729462734628227323833
   PubMedGoogle Scholar
• HirschfieldGMGershwinMEThe immunobiology and pathophysiology of primary biliary cirrhosisAnnu Rev Pathol2013830333023347352
   PubMed Web of Science ®Google Scholar
• BoonstraKBeuersUPonsioenCYEpidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic reviewJ Hepatol20125651181118822245904
   PubMed Web of Science ®Google Scholar
• LazaridisKNTalwalkarJAClinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapyJ Clin Gastroenterol200741549450017450033
   PubMed Web of Science ®Google Scholar
• KimKAJeongSHThe diagnosis and treatment of primary biliary cirrhosisKorean J Hepatol201117317317922102382
   PubMedGoogle Scholar
• SilveiraMGBruntEMHeathcoteJGoresGJLindorKDMayoMJAmerican Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosisHepatology201052134935920578151
   PubMed Web of Science ®Google Scholar
• CancadoELHarrizMThe importance of autoantibody detection in primary biliary cirrhosisFront Immunol2015630926157439
   PubMed Web of Science ®Google Scholar
• ZeinCOAnguloPLindorKDWhen is liver biopsy needed in the diagnosis of primary biliary cirrhosis?Clin Gastroenterol Hepatol200312899515017500
   PubMed Web of Science ®Google Scholar
• ChazouilleresOWendumDSerfatyLMontembaultSRosmorducOPouponRPrimary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapyHepatology19982822963019695990
   PubMed Web of Science ®Google Scholar
• CzajaAJFrequency and nature of the variant syndromes of autoimmune liver diseaseHepatology19982823603659695997
   PubMed Web of Science ®Google Scholar
• FloreaniABaragiottaAGuidoMPrimary biliary cirrhosis-autoimmune hepatitis overlap syndrome: a cause of resistance to ursodeoxycholic treatmentDig Liver Dis200335212812912747633
   PubMedGoogle Scholar
• NeuhauserMBjornssonETreeprasertsukSAutoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosisAm J Gastroenterol2010105234535319888204
   PubMed Web of Science ®Google Scholar
• BobergKMChapmanRWHirschfieldGMOverlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issueJ Hepatol201154237438521067838
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the LiverEASL Clinical Practice Guidelines: management of cholestatic liver diseasesJ Hepatol200951223726719501929
   PubMed Web of Science ®Google Scholar
• KuiperEMZondervanPEvan BuurenHRParis criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndromeClin Gastroenterol Hepatol20108653053420304098
   PubMed Web of Science ®Google Scholar
• FloreaniAFranceschetICazzagonNExtrahepatic autoimmune conditions associated with primary biliary cirrhosisClin Rev Allergy Immunol2015482–319219724809534
   PubMed Web of Science ®Google Scholar
• FoxRISjogren’s syndromeLancet2005366948232133116039337
   PubMed Web of Science ®Google Scholar
• NakamuraTHigashiSTomodaKTsukanoMSugiKPrimary biliary cirrhosis (PBC)-CREST overlap syndrome with coexistence of Sjogren’s syndrome and thyroid dysfunctionClin Rheumatol200726459660016496080
   PubMed Web of Science ®Google Scholar
• CzulFPeytonALevyCPrimary biliary cirrhosis: therapeutic advancesClin Liver Dis201317222924223540499
   PubMed Web of Science ®Google Scholar
• CareyEJAliAHLindorKDPrimary biliary cirrhosisLancet2015386100031565157526364546
   PubMed Web of Science ®Google Scholar
• ParesACaballeriaLRodesJExcellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic AcidGastroenterology2006130371572016530513
   PubMed Web of Science ®Google Scholar
• PouponRChretienYPouponREBalletFCalmusYDarnisFIs ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?Lancet1987185378348362882236
   PubMed Web of Science ®Google Scholar
• CarboneMMellsGFPellsGSex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acidGastroenterology20131443560569.e567 quiz e513–e56423246637
   PubMed Web of Science ®Google Scholar
• CorpechotCAbenavoliLRabahiNBiochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosisHepatology200848387187718752324
   PubMed Web of Science ®Google Scholar
• KuiperEMHansenBEde VriesRADutch PBC Study GroupImproved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acidGastroenterology200913641281128719208346
   PubMed Web of Science ®Google Scholar
• BowlusCLObeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selectionHepat Med20168899527621676
   PubMed Web of Science ®Google Scholar
• PouponRUrsodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of actionClin Res Hepatol Gastroenterol201236Suppl 1S3S1223141891
   PubMed Web of Science ®Google Scholar
• AnguloPDicksonERTherneauTMComparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trialJ Hepatol199930583083510365809
   PubMed Web of Science ®Google Scholar
• AnguloPBattsKPTherneauTMJorgensenRADicksonERLindorKDLong-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosisHepatology199929364464710051462
   PubMed Web of Science ®Google Scholar
• ter BorgPCSchalmSWHansenBEvan BuurenHRDutch PBCSGPrognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-year cohort study involving 297 patientsAm J Gastroenterol200610192044205016848809
   PubMed Web of Science ®Google Scholar
• PouponRELindorKDCauch-DudekKDicksonERPouponRHeathcoteEJCombined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosisGastroenterology199711338848909287980
   PubMed Web of Science ®Google Scholar
• KimWRWiesnerRHPoteruchaJJAdaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidatesLiver Transpl20006448949410915173
   PubMed Web of Science ®Google Scholar
• TalwalkarJAMarkov models in primary biliary cirrhosisGastroenterology200212351750175112404263
   PubMed Web of Science ®Google Scholar
• CorpechotCCarratFBahrAChretienYPouponREPouponRThe effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosisGastroenterology2005128229730315685541
   PubMed Web of Science ®Google Scholar
• WeinmannASattlerTUnoldHPPredictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patientsJ Clin Gastroenterol201549543844725014239
   PubMed Web of Science ®Google Scholar
• LammersWJHirschfieldGMCorpechotCDevelopment and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapyGastroenterology2015149718041812.e180426261009
   PubMed Web of Science ®Google Scholar
• PapastergiouVTsochatzisEARodriguez-PeralvarezMBiochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort studyAliment Pharmacol Ther20133811–121354136424117847
   PubMed Web of Science ®Google Scholar
• LammersWJvan BuurenHRHirschfieldGMLevels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up studyGastroenterology201414761338134925160979
   PubMed Web of Science ®Google Scholar
• LindorKDFarnesoid X receptor agonists for primary biliary cirrhosisCurr Opin Gastroenterol201127328528821297469
   PubMed Web of Science ®Google Scholar
• PellicciariRFiorucciSCamaioniE6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activityJ Med Chem200245173569357212166927
   PubMed Web of Science ®Google Scholar
• FloresAMayoMJPrimary biliary cirrhosis in 2014Curr Opin Gastroenterol201430324525224671010
   PubMed Web of Science ®Google Scholar
• VerbekeLFarreRTrebickaJObeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic ratsHepatology20145962286229824259407
   PubMed Web of Science ®Google Scholar
• HirschfieldGMMasonALuketicVEfficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acidGastroenterology20151484751761.e75825500425
   PubMed Web of Science ®Google Scholar
• KowdleyKJonesDLuketicVThe OCA PBC Study Group, An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBCJ Hepatol201254S13
   Web of Science ®Google Scholar
• NevensFAndreonePMazzellaGA placebo-controlled trial of obeticholic acid in primary biliary cholangitisN Engl J Med2016375763164327532829
   PubMed Web of Science ®Google Scholar
• HirschfieldGMMasonAGordonSCLuketicVLindorKA long term safety extension trial of the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) and UDCA in primary biliary cirrhosis (PBC)Hepatology201154429A
   Web of Science ®Google Scholar
• PetersYHooshmand-RadRPencekRLong-term safety of oeticholic acid in patients wiht primary biliary cirrhosisDig Liver Dis201648e117e118
   Google Scholar
• BeuersUJonesDEMayoMFXR agonist obeticholic acid. Pruritus, a common side effect ameliorated by dose titrationHepatology2014608
   Google Scholar
• Neuschwander-TetriBALoombaRSanyalAJFarnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialLancet2015385997295696525468160
   PubMed Web of Science ®Google Scholar
• HambruchEMiyazaki-AnzaiSHahnUSynthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) miceJ Pharmacol Exp Ther2012343355656722918042
   PubMed Web of Science ®Google Scholar
• FloreaniAFranceschetIPeriniLCazzagonNGershwinMEBowlusCLNew therapies for primary biliary cirrhosisClin Rev Allergy Immunol2015482–326327225331740
   PubMed Web of Science ®Google Scholar
• BeuersUGershwinMEUnmet challenges in immune-mediated hepatobiliary diseasesClin Rev Allergy Immunol2015482–312713125820618
   PubMed Web of Science ®Google Scholar
• InvernizziPGershwinMENew therapeutics in primary biliary cirrhosis: will there ever be light?Liver Int201434216717024393247
   PubMed Web of Science ®Google Scholar
• BaghdasaryanAClaudelTGumholdJDual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2−/− (Abcb4−/−) mouse cholangiopathy model by promoting biliary HCO(−) (3) outputHepatology20115441303131222006858
   PubMed Web of Science ®Google Scholar